Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12677487 | 0.87 | KDM4E (0.52) | KDM4EMAPK1HIF1APAOXFOLH1 | |
| SCHEMBL25543957 | 0.86 | KDM4E (0.47) | KDM4EMAPK1HIF1APAOXFOLH1 | |
| SCHEMBL13057117 | 0.85 | KDM4E (0.54) | KDM4EMAPK1HIF1APAOXFOLH1 | |
| SCHEMBL8513712 | 0.82 | PLA2G2C (0.57) | SIRT6SIRT1PLA2G2CPLA2G2A | |
| SCHEMBL5342627 | 0.82 | KDM4E (0.45) | KDM4EMAPK1HIF1APAOXFOLH1 | |
| SCHEMBL13840537 | 0.81 | PLA2G2C (0.60) | SIRT6SIRT1PLA2G2CPLA2G2AZDHHC7 | |
| SCHEMBL10581621 | 0.81 | PLA2G2C (0.60) | SIRT6SIRT1PLA2G2CPLA2G2AZDHHC7 | |
| SCHEMBL825197 | 0.81 | PAOX (0.49) | KDM4EMAPK1HIF1APAOXFOLH1 | |
| SCHEMBL13715798 | 0.80 | PLA2G2C (0.59) | MAPK1PLA2G2CPLA2G2A | |
| SCHEMBL23061666 | 0.79 | KDM4E (0.60) | KDM4EMAPK1HIF1APAOXFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625898-B2 | Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof | ENZON PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090221471-A1 | PRODRUGS OF VANCOMYCIN WITH HYDROLYSIS RESISTANT POLYMER LINKAGES | ENZON PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090214472-A1 | Interferon-beta polymer conjugates | ENZON PHARMACEUTICALS INC. (NJ) | 2009-08-27 | — | — | US | disclosed |
| US-20090156629-A1 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090047270-A1 | ENZYMATIC ANTICANCER THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080305070-A1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7462687-B2 | Prodrugs of vancomycin with hydrolysis resistant polymer linkages | ENZON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080171013-A1 | POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF | ENZON PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-7301003-B2 | Method of preparing polymers having terminal amine groups | ENZON PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070049725-A1 | Methods of preparing polymers having terminal amine groups | BELROSE PHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047270-A1 | ENZYMATIC ANTICANCER THERAPY | RNASE1, ADA, DCTD | KDM4E 2410/4885MAPK1 4869/4885HIF1A 1607/4885 |
| US-20090156629-A1 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES | RECQL, BLM, SYNCRIP | KDM4E 3296/4885MAPK1 4873/4885HIF1A 3815/4885 |
| US-20080171013-A1 | POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF | ALG1, DDOST, B3GAT3 | KDM4E 4236/4885MAPK1 4296/4885HIF1A 2704/4885 |
| US-20090221471-A1 | PRODRUGS OF VANCOMYCIN WITH HYDROLYSIS RESISTANT POLYMER LINKAGES | SI, DNPEP, PEPD | KDM4E 652/4885MAPK1 3149/4885HIF1A 3836/4885 |
| US-20090214472-A1 | Interferon-beta polymer conjugates | IFNG, IFNAR1, STING1 | KDM4E 4779/4885MAPK1 4548/4885HIF1A 2317/4885 |
| US-20080305070-A1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | CD44, PAICS, PCBP1 | KDM4E 2733/4885MAPK1 4691/4885HIF1A 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.